Until there is a cure for diabetes, Novo Nordisk will stay busy, and as long as diabetes is on the rise, it will likely stay profitable. It is one of the world's leading producers of human insulin, insulin analogues, injection devices, and education materials. It makes modern insulin analogues Levemir and NovoLog (which mimic natural insulin regulation more closely than human insulin) and Saxenda, which treats obesity. The firm also has products in the areas of hemostasis management (blood clotting), human growth hormone, and estrogen replacement therapy. The not-for-profit Novo Nordisk Foundation, through its Novo A/S subsidiary, controls the voting power in Novo Nordisk.